FGFR1 amplification is described as an early event in breast cancer initiation and dysregulated FGFR1 signaling is frequently occurring in breast cancer, and FGFR1 is a target for investigation in ongoing clinical trials for breast cancer therapy (17). This evidence concerns the gene FGFR1 and breast carcinoma.